Results 101 to 110 of about 2,223,573 (201)

[Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].

Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2016
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance significantly limits its use in clinical practice. Study found that TRIM24 was overexpressed in non-small cell lung cancer (NSCLC) tissues and regulate cell growth, cell cycle and apoptosis in lung cell lines.
Haiying LI, Qingling WANG, Haijun BAO, Heng ZHANG, Ying ZHUANG   +4 more
openaire   +2 more sources

Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer

CPT: Pharmacometrics & Systems Pharmacology, 2020
Differences in the effect of gefitinib and chemotherapy on tumor burden in non‐small cell lung cancer remain to be fully understood. Using a Bayesian hierarchical model of tumor size dynamics, we estimated the rates of tumor growth and treatment ...
Mario Nagase, Sergey Aksenov, Hong Yan, James Dunyak, Nidal Al‐Huniti   +4 more
doaj   +1 more source

Comparative Phenotypic and Molecular Characterisation of Feline Oral Squamous Cell Carcinoma Cell Lines Reveals Marked Biological Heterogeneity

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Feline oral squamous cell carcinoma (FOSCC) is the most common oral malignancy, characterised by aggressive local invasion, frequent bone involvement, and poor prognosis. The limited availability of well‐characterised in vitro models has hindered the understanding of tumour heterogeneity and invasive behaviour.
Qaisar Tanveer, Lisa Y. Pang, Colin Farquharson, Gurå Therese Bergkvist   +3 more
wiley   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: A clue to application of gefitinib to hormone-resistant prostate cancer

Oncology Reports, 2006
Understanding the molecular action of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, might allow us to perform more effective therapies for hormone-independent advanced prostate cancer. A DNA microarray study was undertaken to comprehensively analyze the alteration of levels of 1,081 genes after gefitinib treatment in ...
Seiji, Yano, Hideyasu, Matsuyama, Hiroshi, Hirata, Ryo, Inoue, Hiroaki, Matsumoto, Chietaka, Ohmi, Koshiro, Miura, Mutsunori, Shirai, Norio, Iizuka, Katsusuke, Naito   +9 more
openaire   +3 more sources

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, Volume 159, Issue 9, Page 2244-2261, 1 November 2026.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source

MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib

, 2017
Lung adenocarcinoma cells harboring epidermal growth factor receptor (EGFR) mutations are sensitive to EGFR tyrosine kinase inhibitors (TKIs), including gefitinib. Acquired resistance to EGFR-TKIs develops after prolonged treatments. The study was prompt
Huang, Ming-Hung;Lee, Jih-Hsiang;Chang, Ya-Ju;Tsai, Hsin-Hui;Lin, Yu-Lin;Lin, Anya Maan-Yuh;Yang, James Chih-Hsin, 楊志新;林育麟;李日翔   +1 more
core   +1 more source

Epithelial-to-mesenchymal transition correlates with gefitinib resistance in NSCLC cells and the liver X receptor ligand GW3965 reverses gefitinib resistance through inhibition of vimentin

OncoTargets and Therapy, 2017
The role of epithelial-to-mesenchymal transition in cancer drug resistance is increasingly acknowledged. We examined whether epithelial-to-mesenchymal transition affects gefitinib resistance in non-small cell lung cancer (NSCLC) cells. Cell viability was detected by CCK-8 assay, VIM expression levels were determined by quantitative real-time polymerase
Hu,Yong, Zang,Jialan, Qin,Xiaobing, Yan,Dali, Cao,Haixia, Zhou,Leilei, Ni,Jie, Yu,Shaorong, Wu,Jianzhong, Feng,Jifeng   +9 more
openaire   +4 more sources

Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer [PDF]

, 2014
To study epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) resistance mechanisms, we established a novel gefitinib-resistant lung cancer cell line derived from an EGFR-mutant non-small cell lung cancer cell line (PC-9) pretreated with
Hotta, Katsuyuki, Tanimoto, Mitsune, Tabata, Masahiro, Kiura, Katsuyuki, Yasugi, Masayuki, Ichihara, Eiki, Ochi, Nobuaki, Harada, Daijiro, Takigawa, Nagio   +8 more
core   +2 more sources

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source